Hematopoiesis News
Hematopoiesis News is an online resource that provides updates on the latest research in the fields of hematopoiesis, blood, and bone marrow disorders.
Ryvu Therapeutics Announces Dosing of the First Patient in the JASPIS-01 Phase II Study of Dapolsertib (MEN1703/SEL24) for the Treatment of R/R DLBCL
[Ryvu Therapeutics] Ryvu Therapeutics annnounced that the first patient has been dosed in the JASPIS-01 study, a Phase II clinical trial investigating dapolsertib for the treatment of patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL).
Biology As Vulnerability in Follicular Lymphoma: Genetics, Epigenetics, and Immunogenetics
[Blood] Recent advances in high-throughput sequencing, spatial transcriptomics, and imaging technologies uncovered genetic, epigenetic, and immunogenetic features underpinning follicular lymphoma, offering insights into its biology and potential therapeutic vulnerabilities.
Wugen Announces Dosing of First Patients in Pivotal Trial of Off-the-Shelf, Allogeneic, CD7-Targeted CAR-T Cell Therapy WU-CART-007
[Wugen, Inc.] Wugen, Inc. announced the dosing of the first patients in its pivotal Phase II study evaluating WU-CART-007, a potential first-in-class, investigational, anti-CD7 CAR-T cell therapy for pediatric and adult patients with relapsed or refractory T cell acute lymphoblastic leukemia or T cell lymphoblastic lymphoma.
Man Cured Of Sickle Cell Disease In New York Thanks To New Gene Therapy
[Forbes] A 21 year old man in New York has been cured of sickle cell anemia following treatment with a pioneering gene theray. New York resident Sebastien Beauzile was treated with a new gene therapy approach called Lyfgenia, developed by biotech company Bluebird Bio.
Bemcentinib As Monotherapy and in Combination with Low-Dose Cytarabine in Acute Myeloid Leukemia Patients Unfit for Intensive Chemotherapy: A Phase Ib/IIa Trial
[Nature Communications] Scientists reported bemcentinib monotherapy and bemcentinib+low-dose cytarabine combination therapy arms from the completed BerGenBio-funded open-label Phase I/IIb trial in patients unsuitable for intensive chemotherapy.
TP53 Mutations and TET2 Deficiency Cooperate to Drive Leukemogenesis and Establish an Immunosuppressive Environment
[Journal of Clinical Investigation] In mice, combined hematopoietic-specific deletion of TET2 and TP53 resulted in enhanced self-renewal compared to deletion of either gene alone. Tp53/Tet2 double knockout mice developed serially transplantable AML.
NKG2D-Mediated Cytotoxicity of CD4 Cytotoxic T Cells in Multiple Myeloma
[Blood] Researchers performed single-cell RNA sequencing and T cell receptor sequencing on CD4+ T cells sorted from the bone marrow of patients across the stages of myeloma progression.
PI3Kγ in Leukemia: Class IB PI3 Kinase Reemerges As a Cancer-Intrinsic Target
[Blood] Although phosphoinositide 3-kinase gamma (PI3Kγ) inhibition has no direct effect on solid tumor cells, several new studies have nominated PI3Kγ as a cell-intrinsic target in various leukemias, particularly AML. The authors discuss recent progress credentialling PI3Kγ as a bona fide target in leukemia.
Isatuximab Plus Bortezomib, Lenalidomide, and Dexamethasone for Transplant-Ineligible Newly Diagnosed Multiple Myeloma Patients: A Frailty Subgroup Analysis of the IMROZ Trial
[Haematologica] Scientists presented a post-hoc subgroup analysis of IMROZ, a global, Phase III, open-label study investigating isatuximab (Isa) with bortezomib, lenalidomide, and dexamethasone (VRd) followed by Isa-Rd versus VRd followed by Rd in newly diagnosed transplant-ineligible multiple myeloma patients.
Agilent Research Catalyst Award Presented to Columbia University for Professor Pawel Muranski
[Agilent Technologies, Inc.] Agilent Technologies, Inc. announced that Columbia University has received an Agilent Research Catalyst Award on behalf of Dr. Pawel Muranski, an internationally recognized researcher and physician-scientist specializing in bone marrow transplant and cancer cellular immunotherapy.
Selective Translational Control by PABPC1 Phase Separation Regulates Blast Crisis and Therapy Resistance in Chronic Myeloid Leukemia
[Nature Cell Biology] High-throughput CRISPR–Cas9 screening identified poly(A) binding protein cytoplasmic 1 (PABPC1) as a driver for chronic myeloid leukemia progression in the blast crisis stage.
The Proto-Oncogenic miR-106a-363 Cluster Enhances Adverse Risk Acute Myeloid Leukemia through Mitochondrial Activation
[Leukemia] Scientists investigated the clinical and functional role of the miR-106a-363 cluster in adult AML. Overexpression of the miR-106a-363 cluster and its individual members in a murine AML model significantly accelerated leukemogenesis.
Hematopoiesis News curates the top publications and reviews covering the regulation, expression patterns, differentiation and characterization of hematopoietic stem cells, as well as blood and bone marrow disorders. We also feature the latest job postings and upcoming conferences in the hematopoiesis field.
